Get the Stockscreener App
31.18
3.94%
1.207
Hemab Therapeutics Holdings Inc stock is traded at $31.18, with a volume of 110.69K.
It is up +3.94% in the last 24 hours and up +23.12% over the past month.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
See More
Previous Close:
$29.97
Open:
$29.92
24h Volume:
110.69K
Relative Volume:
0.62
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-38.32
EPS:
-0.8135
Net Cash Flow:
-
1W Performance:
-15.19%
1M Performance:
+23.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$29.54
$32.19
1-Week Range:
$29.54
$37.09
52-Week Range:
$23.00
$38.87
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Name
Hemab Therapeutics Holdings Inc
Sector
Industry
Phone
45 2138 7627
Address
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
31.15 | 1.40B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Stock (COAG) Latest News
Price to book forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Enterprise value to revenue forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to earnings forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Enterprise value to EBITDA forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to sales forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics Hldgs Price Target Maintained With a $40.00/Share by HC Wainwright & Co. - Moomoo
Hemab Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:COAG) - TradingView
COAG Forecast — Price Target — Prediction for 2027 - TradingView
COAG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress - The Manila Times
Hemab brings nine bleeding-disorder studies to ISTH 2026 in Paris - Stock Titan
Enterprise value to EBIT forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P TMI Index - marketscreener.com
This GE Vernova analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
COAG Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Hemab Therapeutics (COAG) stake rises as RA Capital buys 67,669 shares - Stock Titan
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Wedbush initiates Hemab Therapeutics stock with outperform rating - Investing.com
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
Hemab Therapeutics Holdings Inc Stock (COAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hemab Therapeutics Holdings Inc Stock (COAG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jun 15 '26 |
Buy |
24.89 |
6,146 |
152,974 |
6,383,114 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 19 '26 |
Buy |
24.97 |
3,802 |
94,936 |
6,375,972 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
1.21%
3.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):